ZAGREB, Feb 8 (Hina) - The biggest pharmaceutical company in Central and Eastern Europe, Croatia's Pliva, and The Althexis Company from the United States on Monday signed an agreement on cooperation in developing and placing a new
antibiotic on the market. Pliva will invest up to US$14.4 million in the project in the next three years, the Pliva management reported. The Structure-based Drug Design (SBDD) technology will be used in the research. According to the agreement, Pliva has the exclusive right of placing new drugs on markets, excluding Japan, South Korea and Taiwan, markets to which the Althexis holds rights. Both companies however keep sales right on the Chinese market. During the research in developing new antibiotics, the two companies will exchange knowledge, including results of pre-clinical and clinical research, and use them in further activities and research. The Alth
ZAGREB, Feb 8 (Hina) - The biggest pharmaceutical company in
Central and Eastern Europe, Croatia's Pliva, and The Althexis
Company from the United States on Monday signed an agreement on
cooperation in developing and placing a new antibiotic on the
market.
Pliva will invest up to US$14.4 million in the project in the next
three years, the Pliva management reported.
The Structure-based Drug Design (SBDD) technology will be used in
the research.
According to the agreement, Pliva has the exclusive right of
placing new drugs on markets, excluding Japan, South Korea and
Taiwan, markets to which the Althexis holds rights. Both companies
however keep sales right on the Chinese market.
During the research in developing new antibiotics, the two
companies will exchange knowledge, including results of pre-
clinical and clinical research, and use them in further activities
and research.
The Althexis Company from Boston demonstrates a revolutionary
approach in tracing and developing drugs which help smaller
companies with less capital to successfully compete even with
largest pharmaceutical companies.
(hina) it jn/ha